Propanc Biopharma, Inc. filed a Form 8-K on October 29, 2026, disclosing that it received a written notice from Nasdaq on October 23, 2026, stating the company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Key Highlights

  • Non-compliance notice received: Nasdaq informed the company on October 23, 2026, that its common stock failed the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
  • 30-day trigger: The deficiency was based on the closing bid price falling below $1.00 for 30 consecutive business days prior to October 21, 2026.
  • No cure period available: The company is not eligible for the standard 180-calendar-day compliance period because it had previously effected a reverse stock split within the prior one-year period, per Listing Rule 5810(c)(3)(A)(iv).
  • Delisting date set: Securities are scheduled to be delisted from The Nasdaq Capital Market on November 2, 2026, unless an appeal is requested by October 30, 2026.
  • Appeal intended: The company disclosed it intends to request the appeal by the October 30, 2026 deadline, stating it "believes it has cured the Bid Price Requirement deficiency subsequent to the receipt and date of the Notice."
  • Stay of delisting: Requesting an appeal will stay the delisting, and the company's securities will remain on The Nasdaq Capital Market until the Panel's decision.

Propanc Biopharma Faces Nasdaq Delisting After Bid Price Breach

According to the Form 8-K filed with the SEC, Propanc Biopharma, Inc. (NASDAQ:PPCB) received a formal written notice from the Listing Qualifications Department of The Nasdaq Stock Market on October 23, 2026. The notice indicated the company is out of compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum closing bid price of $1.00 per share. The company's common stock failed to meet this threshold over 30 consecutive business days prior to October 21, 2026.

The filing notes that, under ordinary circumstances, a company would receive a 180-calendar-day period to demonstrate compliance. However, the company disclosed it is ineligible for that grace period because it had previously effected a reverse stock split during the prior one-year period, disqualifying it under Nasdaq Listing Rule 5810(c)(3)(A)(iv). As a result, the notice states that the company's securities will be delisted on November 2, 2026, unless the company appeals the determination to a hearings panel by October 30, 2026. The filing states that requesting an appeal would stay the delisting pending the panel's decision.

The company disclosed its intention to file the appeal by the stated deadline, citing a belief that the bid price deficiency has been cured since the notice was received. The filing also enumerated potential consequences if delisting were ultimately to occur, including "reducing the liquidity and market price of the Company's common stock," limiting investor acquisition of shares, restricting use of registration statements for offering securities, and "impairing the Company's ability to provide equity incentives to its employees." The filing noted the notice does not affect the company's business operations or its SEC reporting obligations. The filing contains forward-looking statements that the company cautioned are subject to significant risks and uncertainties.

What Was Disclosed

Propanc Biopharma disclosed receipt of a Nasdaq non-compliance notice for failure to maintain a $1.00 minimum bid price, an ineligibility for the standard cure period due to a prior reverse stock split, a November 2, 2026 delisting deadline, and the company's intent to appeal by October 30, 2026.